Aratana Therapeutics Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Aratana Therapeutics (PETX) Tops Q2 EPS by 1c
August 3, 2017 5:18 PM EDTAratana Therapeutics (NASDAQ: PETX) reported Q2 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $5.16 million versus the consensus estimate of $4.73 million.
As of June 30, 2017, Aratana had approximately $80.7 million in cash, cash equivalents, restricted cash and short-term investments,... More
